Patient Guide: All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 13 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06956170
Status: ACTIVE_NOT_RECRUITING
Condition: Multiple Myeloma
Phase: PHASE3

Where You Can Participate

This study is available at 13 locations across the country.

Top locations include:
  • • Nagoya City, Aichi-Ken
  • • Kamogawa City, Chiba-Ken
  • • Kashiwa City, Chiba-Ken
  • • And 10 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma - Join Clinical Trial NCTNCT06956170

How to Join This Clinical Trial - NCTNCT06956170

Learn how to participate in this PHASE3 trial studying an investigational therapy for Multiple Myeloma. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Multiple Myeloma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Multiple Myeloma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT06956170 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 13 locations. Find a study site near you:

Clinical Research Site

Nagoya City, Aichi-Ken 467-8602 - Japan

Status: Contact for availability

Clinical Research Site

Kamogawa City, Chiba-Ken 296-8602 - Japan

Status: Contact for availability

Clinical Research Site

Kashiwa City, Chiba-Ken 277-8567 - Japan

Status: Contact for availability

Clinical Research Site

Matsuyama City, Ehime-Ken 790-8524 - Japan

Status: Contact for availability

Clinical Research Site

Fukushima City, Fukushima-Ken 960-1295 - Japan

Status: Contact for availability

Clinical Research Site

Maebashi City, Gunma-Ken 371-8511 - Japan

Status: Contact for availability

Clinical Research Site

Shibukawa City, Gunma-Ken 377-0280 - Japan

Status: Contact for availability

Clinical Research Site

Iwate, Iwate-Ken 028-3695 - Japan

Status: Contact for availability

Clinical Research Site

Okayama City, Okayama-Ken 701-1192 - Japan

Status: Contact for availability

Clinical Research Site

Osaka, Osaka-Fu 565-0871 - Japan

Status: Contact for availability

And 3 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Multiple Myeloma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships